Literature DB >> 31917838

Both sides now: losses and gains of mutant CALR.

Ann Mullally1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31917838      PMCID： PMC6952827          DOI： 10.1182/blood.2019003820

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Calcium signaling and cell proliferation.

Authors:  Mauro Cunha Xavier Pinto; Alexandre Hiroaki Kihara; Vânia A M Goulart; Fernanda M P Tonelli; Katia N Gomes; Henning Ulrich; Rodrigo R Resende
Journal:  Cell Signal       Date:  2015-08-11       Impact factor: 4.315

2.  Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.

Authors:  Christian A Di Buduo; Vittorio Abbonante; Caroline Marty; Francesco Moccia; Elisa Rumi; Daniela Pietra; Paolo M Soprano; Dmitry Lim; Daniele Cattaneo; Alessandra Iurlo; Umberto Gianelli; Giovanni Barosi; Vittorio Rosti; Isabelle Plo; Mario Cazzola; Alessandra Balduini
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

3.  Targeting the CALR interactome in myeloproliferative neoplasms.

Authors:  Elodie Pronier; Paolo Cifani; Tiffany R Merlinsky; Katharine Barr Berman; Amritha Varshini Hanasoge Somasundara; Raajit K Rampal; John LaCava; Karen E Wei; Friederike Pastore; Jesper Lv Maag; Jane Park; Richard Koche; Alex Kentsis; Ross L Levine
Journal:  JCI Insight       Date:  2018-11-15

4.  Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.

Authors:  Shannon Elf; Nouran S Abdelfattah; April J Baral; Danielle Beeson; Jeanne F Rivera; Amy Ko; Natalie Florescu; Gabriel Birrane; Edwin Chen; Ann Mullally
Journal:  Blood       Date:  2017-12-29       Impact factor: 22.113

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

6.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Authors:  Shannon Elf; Nouran S Abdelfattah; Edwin Chen; Javier Perales-Patón; Emily A Rosen; Amy Ko; Fabian Peisker; Natalie Florescu; Silvia Giannini; Ofir Wolach; Elizabeth A Morgan; Zuzana Tothova; Julie-Aurore Losman; Rebekka K Schneider; Fatima Al-Shahrour; Ann Mullally
Journal:  Cancer Discov       Date:  2016-03-07       Impact factor: 39.397

7.  Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.

Authors:  Marito Araki; Yinjie Yang; Nami Masubuchi; Yumi Hironaka; Hiraku Takei; Soji Morishita; Yoshihisa Mizukami; Shin Kan; Shuichi Shirane; Yoko Edahiro; Yoshitaka Sunami; Akimichi Ohsaka; Norio Komatsu
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

8.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Authors:  Ilyas Chachoua; Christian Pecquet; Mira El-Khoury; Harini Nivarthi; Roxana-Irina Albu; Caroline Marty; Vitalina Gryshkova; Jean-Philippe Defour; Gaëlle Vertenoeil; Anna Ngo; Ann Koay; Hana Raslova; Pierre J Courtoy; Meng Ling Choong; Isabelle Plo; William Vainchenker; Robert Kralovics; Stefan N Constantinescu
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Authors:  D Pietra; E Rumi; V V Ferretti; C A Di Buduo; C Milanesi; C Cavalloni; E Sant'Antonio; V Abbonante; F Moccia; I C Casetti; M Bellini; M C Renna; E Roncoroni; E Fugazza; C Astori; E Boveri; V Rosti; G Barosi; A Balduini; M Cazzola
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528
  10 in total
  2 in total

1.  Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Authors:  Manjola Balliu; Laura Calabresi; Niccolò Bartalucci; Simone Romagnoli; Laura Maggi; Rossella Manfredini; Matteo Lulli; Paola Guglielmelli; Alessandro Maria Vannucchi
Journal:  Blood Adv       Date:  2021-04-27

2.  Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes.

Authors:  Laura Villani; Adriana Carolei; Vittorio Rosti; Margherita Massa; Rita Campanelli; Paolo Catarsi; Carlotta Abbà; Robert Peter Gale; Giovanni Barosi
Journal:  Genes (Basel)       Date:  2021-08-20       Impact factor: 4.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.